Drug Discovery Alliances’ management has carefully identified and selected a portfolio of world class contract research and manufacturing companies to be formally and contractually represented by Drug Discovery Alliances.
Understand the client’s goals and technical requirements for each project under CDA.
Tailor a solution that can involve one or more suppliers that provide the best solution to accomplish the goals and requirements for each and every project for the client.
The companies in the Drug Discovery Alliances portfolio have a proven track record in assisting pharmaceutical clients with IND enabling programs to the point of licensing and development programs to commercial readiness. By working with our organization our clients can take advantage of a seamless and integrated approach to drug discovery and development with a portfolio of companies that have a proven track record of success in pharmaceutical research and development. Our client can realize quick access to a number of services by just making one phone call.
That need was the effective partnership building between outsourcing providers and outsourcing contractors in the United States. Her services have a provided her clients with not only a substantial, but sustained revenue stream.
About Deborah Minor, Ph. D.
Deborah Minor, Ph.D. has close to two decades of business development experience marketing contract services, drug licensing and new technologies to the pharmaceutical industry. She founded Drug Discovery Alliances, Inc. in 2001 with the primary business focus to setup alliances in the pharmaceutical industry between contractors and pharmaceutical companies to help facilitate drug research and development. Over the past two decades her company has generated close to 100 million dollars in revenues for the contractors represented by her company. Deborah obtained a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill and has worked as an organic chemist for Rhone Poulenc. After graduate school she moved on to work for Accelyrs and subsequently MDL marketing molecular modeling technologies and databases including Beilstein, Crossfire to the pharmaceutical industry.
Deborah Minor, Ph.D.
- Process Research
- Medicinal Chemistry
- Handling of DEA controlled substances
- Impurity and Metabolite Characterization
- Sourcing of Reference Standards
- Route Scouting
- Free Screening, SFC separations under cGMP
- Stability studies
- Patent and Intellectual property challenges
- Phase 1 to Commercial API Manufacturing
- Sourcing of raw materials, API’s and intermediates, globally
- In-Vitro ADME toxicology
- Pre-formulation work, salt and polymorph screens
- Final Dose Manufacturing including solid dose and IV, pre-IND to commercial